Furthermore, within-patient variability of the peak effect in blood glucose lowering from one injection to the next can become a major contributing factor to nocturnal hypoglycemia, limiting the ability to achieve optimal glycemic control (16). Therefore, hypoglycemia, including nocturnal hypoglycemia, still poses a clinical concern (17,18). This supports the need for an insulin with lower variability and thus potentially also a lower risk of hypoglycemia that may encourage treatment adherence and safer achievement of glycemic control. Moreover, it also supports the need to continue research and development of insulins which closely mimic the normal physiologic profile